A Functional Wound Dressing as a Potential Treatment for Cutaneous Leishmaniasis

Alexandrino-Junior, Francisco; Silva, Káttya Gyselle de Holanda e; Freire, Marjorie Caroline Liberato Cavalcanti; Lione, Viviane de Oliveira Freitas; Cardoso, Elisama Azevedo; Marcelino, Henrique Rodrigues; Genre, Julieta; Oliveira, Anselmo Gomes de; Egito, Eryvaldo Sócrates Tabosa do

doi:10.3390/pharmaceutics11050200

Cited by 13 publications

(9 citation statements)

References 75 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical treatments have many advantages: they are easy to administer, do not require hospitalization or other infrastructure, favor patient commitment, are low cost and have fewer toxic side effects [8,9,10].…”

Section: Introductionmentioning

confidence: 99%

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis

et al. 2019

View full text Add to dashboard Cite

Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimoniate (MA). With the aim of developing an alternative topical treatment for CL, a gel-based formulation with 30% MA was prepared and its physicochemical properties, stability and rheological behavior were studied. The following were assessed: drug release on propylene hydrophilic membranes ex vivo human skin permeation, tolerance in healthy volunteers, cytotoxicity in three cell lines and anti-leishmanial activity against Leishmania infantum promastigotes and amastigotes. The MA gel formulation was found to have suitable pH, and good spreadability and stability. Low quantities of pentavalent antimony (SbV) were observed in release and permeation tests, whereas retention was high in both non-damaged and damaged skin (71,043.69 ± 10,641.57 and 10,728 ± 2254.61 µg/g/cm2 of SbV, respectively). The formulation did not have a toxic effect on the cell lines, and presented lower SbV IC50 values against amastigotes (15.76 ± 4.81 µg/mL) in comparison with the MA solution. The high amount of drug retained in the skin and the SbV IC50 values obtained suggest that this semi-solid dosage form has potential as an alternative treatment of CL.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A rather slow and gradual release of Amp B (74% after 97 h) was reported but did not impact on the system's anti-leishmanial activity. They were found to be highly toxic against L. amazonensis and L. braziliensis with a promastigote death rate of 100% and 99%, respectively, within the first 24 h [111].…”

Section: Nanostructures As Carriers For Anti-leishmanial Drugsmentioning

confidence: 99%

Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis

et al. 2022

View full text Add to dashboard Cite

Nanomedicine strategies were first adapted and successfully translated to clinical application for diseases, such as cancer and diabetes. These strategies would no doubt benefit unmet diseases needs as in the case of leishmaniasis. The latter causes skin sores in the cutaneous form and affects internal organs in the visceral form. Treatment of cutaneous leishmaniasis (CL) aims at accelerating wound healing, reducing scarring and cosmetic morbidity, preventing parasite transmission and relapse. Unfortunately, available treatments show only suboptimal effectiveness and none of them were designed specifically for this disease condition. Tissue regeneration using nano-based devices coupled with drug delivery are currently being used in clinic to address diabetic wounds. Thus, in this review, we analyse the current treatment options and attempt to critically analyse the use of nanomedicine-based strategies to address CL wounds in view of achieving scarless wound healing, targeting secondary bacterial infection and lowering drug toxicity.

show abstract

“…The most commonly used drugs against CL are pentavalent antimonials, paromomycin, liposomal amphotericin B (AmBisome, AmB) and oral miltefosine [ 11 , 12 , 13 ], which have multiple adverse effects. AmB has replaced antimony as a first-line therapy for treatment, but its use is limited due to the difficulty of administration, as well as its high cost [ 14 , 15 , 16 ]. Leishmania ( L .)…”

Section: Introductionmentioning

confidence: 99%

Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis

et al. 2023

View full text Add to dashboard Cite

Cutaneous Leishmaniasis (CL), a neglected vector-borne disease caused by protozoan parasite Leishmania major (L. major), is a major public health concern, and the development of new strategies to reduce the disease incidence has become a top priority. Advances in immunoinformatics and in-silico epitope prediction could be a promising approach to designing a finest vaccine candidate. In this study, we aimed to design a peptide-based vaccine against CL using computational tools and identified ten B-cell-derived T-cell epitopes from the glycoprotein gp63 of L. major. All of the potential immunodominant epitopes were used to design a vaccine construct along with a linker and an adjuvant at the N-terminal for enhancing its immunogenicity. Additionally, many characteristics of the proposed vaccine were examined, and it was confirmed to be non-allergenic, non-toxic, and thermally stable. To assess the vaccine interaction with the innate immune toll-like receptor-4 (TLR-4), a 3D structure of the vaccine construct was developed. Molecular docking and molecular dynamic simulation were used to confirm the binding and to assess the stability of the vaccine-TLR4 complex and interactions, respectively. In conclusion, our multi-epitope vaccine will provide a gateway to analyze the protein function of a potential vaccine candidate against CL.

show abstract

A Functional Wound Dressing as a Potential Treatment for Cutaneous Leishmaniasis

Cited by 13 publications

References 75 publications

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis

Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis

Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis

Contact Info

Product

Resources

About